ABCC2 p.Leu23Arg
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 21143116
[PubMed]
He SM et al: "Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1)."
No.
Sentence
Comment
335
Some other NSAIDs including sulindac were found to have a similar effect in human lung cancer cell lines DLKP, A549, COR L23P and COR L23R and in a human leukaemia line HL60/ADR [229], although it is unrelated to the action of these drugs on cyclooxygenases.
X
ABCC2 p.Leu23Arg 21143116:335:134
status: NEW
PMID: 11839251
[PubMed]
Connolly L et al: "A new monoclonal antibody, P2A8(6), that specifically recognizes a novel epitope on the multidrug resistance-associated protein 1 (MRP1), but not on MRP2 nor MRP3."
No.
Sentence
Comment
43
Control cell lines The multidrug resistant nonsmall cell lung carcinoma cell line, COR-L23R (made resistant by exposure to increasing concentrations of adriamycin(26)) and its drug-sensitive counterpart, COR-L23S, were used as control cells for the presence/absence of MRP1.
X
ABCC2 p.Leu23Arg 11839251:43:87
status: NEW44 Overexpression of MRP1 in COR-L23R cells compared with the parental COR-L23S had been confirmed in previous studies using other commercially available antibodies raised against MRP1 (MRPr1, MRPm5, MRPm6,(15) QCRL-1, and QCRL-3(16)) (Alexis Biochemicals, San Diego, CA).
X
ABCC2 p.Leu23Arg 11839251:44:30
status: NEW56 These supernatants were also screened by Western blot analysis, CONNOLLY ET AL.334 against cell membrane preparations of the MRP1-overexpressing COR-L23R cell line.
X
ABCC2 p.Leu23Arg 11839251:56:150
status: NEW76 MAb P2A8(6) detects a 190-kDa band (associated with the presence of MRP1) on preparations from drug resistant cells (COR-L23R) and MRP1-transfected cells (2008 MRP1).
X
ABCC2 p.Leu23Arg 11839251:76:121
status: NEW88 The antibody-peptide complex was centrifuged at 15,000 3 g in a microcentrifuge (Heraeus Instruments, Hanau, Germany) and the supernatantremoved carefully before use in Western blotting studies on COR-L23R cells.
X
ABCC2 p.Leu23Arg 11839251:88:201
status: NEW91 Heat treatment appears to alter the expression of the antigen recognizedby MAb MRPr1 on the MRP1 protein expressed by the drug-resistant cells (COR-L23R).
X
ABCC2 p.Leu23Arg 11839251:91:148
status: NEW96 Heat treatment does not appear to destroy the antigen recognized by MAb PA8(6) on the MRP1-drug resistant cells (COR-L23R) or MRP1-transfected cells (2008 MRP1).
X
ABCC2 p.Leu23Arg 11839251:96:117
status: NEW102 MAb P2A8(6), like the well-characterized MRPr1 MAb, detects a 190-kDa band (associatedwith the presence of MRP1) in the COR-L23R and MRP1-transfected 2008 MRP1 cell lines.
X
ABCC2 p.Leu23Arg 11839251:102:124
status: NEW103 These antibodies also detect a very low basal level of MRP1 expressed in the parental sensitiveCOR-L23R and parental nontransfected2008 cell lines.
X
ABCC2 p.Leu23Arg 11839251:103:99
status: NEW109 Both MAbs detect MRP1 in the COR-L23R, HL60ADR, A549 and RPMI 2650 melphalan-selected cells.
X
ABCC2 p.Leu23Arg 11839251:109:33
status: NEW115 MRP2 is undetectable in the COR-L23R, COR-L23S, HL60ADR, HL60S, DLKP, RPMI 2650, and RPMI 2650 taxol-selected cells.
X
ABCC2 p.Leu23Arg 11839251:115:32
status: NEW117 MRP3 Heat treatment studies were carried out on the MRP1 overexpressing drug selected COR-L23R cell line and the MRP1-transfected cell line 2008 MRP1 prior to electrophoresis (cell lysates in loading buffer, placed in a water-bath for 3 min @ 100°C) (Figs.
X
ABCC2 p.Leu23Arg 11839251:117:91
status: NEW119 These studies showed that heat treatment appears to decrease antigen recognition (observed mainly by a decrease in stainingintensityin the lower area of the MRP1 protein band on the Western blot) by the MRPr1 antibody in the drug-selectedCOR-L23R cell line.
X
ABCC2 p.Leu23Arg 11839251:119:242
status: NEW121 The antigen recognized by antibody P2A8(6) appears to be heat stable in the drug selected COR-L23R cell line and the MRP1-transfected 2008 MRP1 cell line, as no decrease in staining intensity in the MRP1 protein band was observed following heat treatment (Fig. 4).
X
ABCC2 p.Leu23Arg 11839251:121:94
status: NEW124 MRP1 expressionwas detectedby both these MAbs in the COR-L23R, HL60ADR, A549 and RPMI 2650 melphalan-selected cell lines.
X
ABCC2 p.Leu23Arg 11839251:124:57
status: NEW134 SUMMARY OF MRP1, MRP2, AND MRP3 PROTEIN EXPRESSION LEVELS AS DETERMINED BY WESTERN BLOT ANALYSIS Protein expression levels (as determined by Western blot analysis) MRPr1 M2III-6 M3II-21 Cell line P2A8(6) (MRP1) (MRP2) (MRP3) COR-L23R 1 1 - - COR-L23S 1/2 1/2 - - HL60ADR 1 1 - - HL60S - - - - DLKP - - - - DLKPA - - - - A549 1 1 1 - RPMI 2650 - 1/2 - - Parental RPMI 2650 - - - - Taxol-selected RPMI 2650 1 1 1 - Melphalan-selected Key: -: Undetectable levels; 1: Over-expression; and 1/2: Very low basal levels.
X
ABCC2 p.Leu23Arg 11839251:134:229
status: NEW139 Strong staining was seen on the non-Pgp MDR cell line COR-L23R and the MRP1-transfected 2008 ovarian carcinoma cell line but not their parental drug sensitive or nontransfected cell lines.
X
ABCC2 p.Leu23Arg 11839251:139:58
status: NEW146 MAb P2A8(6) shows strong plasma-membranousstaining of the MRP1 overexpressingdrug selected cells (COR-L23R) and the MRP1-transfected cells (2008 MRP1).
X
ABCC2 p.Leu23Arg 11839251:146:102
status: NEW
PMID: 11334731
[PubMed]
Liang Y et al: "Selection with melphalan or paclitaxel (Taxol) yields variants with different patterns of multidrug resistance, integrin expression and in vitro invasiveness."
No.
Sentence
Comment
135
Circumvention studies with verapamil and cyclosporin A The Pgp-overexpressing cell line DLKP-A and MRP1-overexpressing cell line COR-L23R were used as Fig. 1.
X
ABCC2 p.Leu23Arg 11334731:135:133
status: NEW152 Table 3 Circumvention studies with verapamil and cyclosporin A in the RPMI-2650 cell line and its taxol- and melphalan-resistant variantsa Cell line IC50 (nM) ADR ADR+ verapamil (1 mg/ml) ADR+ cyclosporin A (1 mg/ml) COR-L23R 2097Æ364 938Æ146 1435Æ129 DLKP-A 5750Æ275 441Æ157 1582Æ167 RPMI-2650 110Æ37 59Æ18 77Æ19 RPMI-2650Tx 5750Æ224 2171Æ195 497Æ118 RPMI-2650Ml 690Æ138 48Æ15 304Æ125 ADR, doxorubicin.
X
ABCC2 p.Leu23Arg 11334731:152:221
status: NEW136 Circumvention studies with verapamil and cyclosporin A The Pgp-overexpressing cell line DLKP-A and MRP1-overexpressing cell line COR-L23R were used as Fig. 1.
X
ABCC2 p.Leu23Arg 11334731:136:133
status: NEW153 Table 3 Circumvention studies with verapamil and cyclosporin A in the RPMI-2650 cell line and its taxol- and melphalan-resistant variantsa Cell line IC50 (nM) ADR ADR+ verapamil (1 mg/ml) ADR+ cyclosporin A (1 mg/ml) COR-L23R 2097364 938146 1435129 DLKP-A 5750275 441157 1582167 RPMI-2650 11037 5918 7719 RPMI-2650Tx 5750224 2171195 497118 RPMI-2650Ml 690138 4815 304125 ADR, doxorubicin.
X
ABCC2 p.Leu23Arg 11334731:153:221
status: NEW
PMID: 11864633
[PubMed]
Bandi N et al: "Budesonide reduces multidrug resistance-associated protein 1 expression in an airway epithelial cell line (Calu-1)."
No.
Sentence
Comment
67
The doxorubicin-resistant COR-L23R cells used as the MRP1 positive controls in the Western blot and vincristine sensitivity studies were N. Bandi, U.B. Kompella / European Journal of Pharmacology 437 (2002) 9-1710 obtained from Dr. Donald W. Miller (Nebraska Medical Center, Omaha, NE).
X
ABCC2 p.Leu23Arg 11864633:67:30
status: NEW81 Cell lysates of the human lung carcinoma cells, COR-L23R, used as MRP1 positive controls (Thomas et al., 1994) in the Western blot analysis, were loaded at 10-mg protein.
X
ABCC2 p.Leu23Arg 11864633:81:52
status: NEW125 In this study, MRP1 overexpressing COR-L23R cells seeded at densities of 5000 cells/well in 96-well plates were treated with various concentrations of vincristine (0.1-5 nM) with or without budesonide (10 mM).
X
ABCC2 p.Leu23Arg 11864633:125:39
status: NEW188 * Indicates significant difference from controls in the accumulation and efflux studies. Fig. 6. Effect of the budesonide on the vincristine-mediated cytotoxicity in the COR-L23R cells.
X
ABCC2 p.Leu23Arg 11864633:188:174
status: NEW189 The sensitivity of the COR-L23R cells to the vincristine was determined in the presence and absence of budesonide (10 mM) using an MTT assay.
X
ABCC2 p.Leu23Arg 11864633:189:27
status: NEW222 In order to determine whether budesonide enhances the chemosensitivity of anticancer drugs, we determined the cytotoxic effects of vincristine with and without budesonide in COR-L23R cells.
X
ABCC2 p.Leu23Arg 11864633:222:178
status: NEW224 The results of our study indicated that budesonide, at concentrations devoid of cytotoxicity (Table 1a), enhanced the sensitivity of COR-L23R to vincristine (Fig. 6), possibly by inhibiting MRP1 expression.
X
ABCC2 p.Leu23Arg 11864633:224:137
status: NEW226 However, as the vincristine studies were performed in MRP1 overexpressing COR-L23R cells, we believe that our results are consistent with the inhibition of the MRP1-mediated efflux of vincristine.
X
ABCC2 p.Leu23Arg 11864633:226:78
status: NEW191 * Indicates significant difference from controls in the accumulation and efflux studies. Fig. 6. Effect of the budesonide on the vincristine-mediated cytotoxicity in the COR-L23R cells.
X
ABCC2 p.Leu23Arg 11864633:191:174
status: NEW192 The sensitivity of the COR-L23R cells to the vincristine was determined in the presence and absence of budesonide (10 mM) using an MTT assay.
X
ABCC2 p.Leu23Arg 11864633:192:27
status: NEW225 In order to determine whether budesonide enhances the chemosensitivity of anticancer drugs, we determined the cytotoxic effects of vincristine with and without budesonide in COR-L23R cells.
X
ABCC2 p.Leu23Arg 11864633:225:178
status: NEW227 The results of our study indicated that budesonide, at concentrations devoid of cytotoxicity (Table 1a), enhanced the sensitivity of COR-L23R to vincristine (Fig. 6), possibly by inhibiting MRP1 expression.
X
ABCC2 p.Leu23Arg 11864633:227:137
status: NEW229 However, as the vincristine studies were performed in MRP1 overexpressing COR-L23R cells, we believe that our results are consistent with the inhibition of the MRP1-mediated efflux of vincristine.
X
ABCC2 p.Leu23Arg 11864633:229:78
status: NEW